Chimeric Antigen Receptor T Cells Targeting EGFRvIii in Patients with Recurrent Glioblastoma: Does Route of Administration Affect Clinical Outcomes?

摘要

Problem: Glioblastoma is the most common and most lethal primary brain cancer in adults. Even after multimodal therapy, glioblastoma carries a poor prognosis with a median survival of 15 months. Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a revolutionary form of immunotherapy in certain hematopoietic malignancies. However, results from early clinical studies for CAR T cell therapy in glioblastoma are equivocal. Purpose: The purpose of this study is to examine how mode of administration of anti-EGFRvIII CAR T cells affects clinical outcomes for patients with glioblastoma. Research Question: Is there a significant difference in safety and overall survival between glioblastoma patients receiving anti-EGFRvIII CAR T-cells administered intracranially versus intravenously? Methods: Patients with evidence of recurrent glioblastoma expressing EGFRvIII who meet study guidelines will be administered a dose of anti-EGFRvIII CAR T-cells either intracranially or intravenously.Outcomes: After one year two clinical outcomes will be evaluated, namely the number of adverse events in each study arm and the overall survival in each study arm. Mann-Whitney U and Chi-Square tests will be used to evaluate differences.Benefits: Novel treatment strategies for the treatment of glioblastoma are urgently warranted. The results of this study may highlight one way to optimize CAR T cell therapy for glioblastoma patients for better clinical outcomes.